✦ LIBER ✦

Prostate cancer: PSA enzymatic activity to assess disease aggressiveness

✍ Scribed by Fenner, Annette

Book ID: 121298708
Publisher: Nature Publishing Group
Year: 2013
Tongue: English
Weight: 48 KB
Volume: 10
Category: Article
ISSN: 1759-4812
DOI: 10.1038/nrurol.2013.187

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prostate cancer: Promising biomarkers re

Prostate cancer: Promising biomarkers related to aggressive disease

✍ Ribeiro da Silva, M.N.; Tobias-Machado, M.; Lima Pompeo, A.C.; Reis, L.O.; da Si 📂 Article 📅 2012 🏛 Elsevier ⚖ 220 KB

1731 PSA VOLATILITY INDEX (PVI): USING P

1731 PSA VOLATILITY INDEX (PVI): USING PSA VARIATION AND AUA SYMPTOM SCORE TO ASSESS RISK FOR PROSTATE CANCER

✍ Fishman, Andrew; Tareen, Basir; Choudhury, Muhammad; Phillips, John 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 96 KB

807 MODEL TO PREDICT AGGRESSIVE PROSTATE

807 MODEL TO PREDICT AGGRESSIVE PROSTATE CANCER ON PATIENTS WITH PSA 2.5-10

✍ F. Gomez Veiga; J. Ponce; S. Pertega; E. Romero; P. Casas; E. Rosado; I. Gomez; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 317 KB

UP.49: Value of Complex PSA Percentage t

UP.49: Value of Complex PSA Percentage to Define Prostate Cancer Aggressiveness in Patients with Total PSA Between 2.5 And 10ng/Dl

✍ A. Zarraonandia; F. Gómez Veiga; J. Ponce; S. Pertega; S. Breijo; D. López; L. C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 72 KB

Clinical utility of apparent diffusion c

Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: Can ADC values contribute to assess the aggressiveness of prostate cancer?

✍ Yasushi Itou; Katsuyuki Nakanishi; Yoshifumi Narumi; Yasuko Nishizawa; Hideaki T 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB 👁 1 views

## Abstract ## Purpose To retrospectively evaluate the relationship between apparent diffusion coefficient (ADC) values and Gleason score (GS) in prostate cancer. ## Methods A total of 60 patients who underwent radical prostatectomy for clinically localized prostate cancer were selected for this

805 PSA-VELOCITY AND ARTIFICIAL NEURAL N

805 PSA-VELOCITY AND ARTIFICIAL NEURAL NETWORK (ANN)-VELOCITY TO DIFFERENTIATE PROSTATE CANCER FROM BENIGN PROSTATIC DISEASE

✍ C. Stephan; N. Büker; H. Cammann; C. Xu; H.A. Meyer; S.A. Loening; K. Jung 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 317 KB